莎拉试验：关于神经激素阻滞剂在预防蒽环类药物所致心脏毒性中作用的更多证据。
The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.
作者信息
Mecinaj Albulena, Vinje-Jakobsen Victoria, Ngo Doan T M, Sverdlov Aaron L, Myhre Peder L
机构信息
Department of Cardiology, Akershus University Hospital, Lørenskog, Norway.
K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
出版信息
Heart Fail Rev. 2025 May;30(3):627-631. doi: 10.1007/s10741-025-10495-1. Epub 2025 Feb 17.
Abstract
This mini-review highlights the results of the SARAH trial, which evaluated the efficacy of sacubitril/valsartan in preventing subclinical cardiac dysfunction in patients undergoing anthracycline-based chemotherapy. The trial demonstrated a significant reduction in GLS decline in the treatment group compared to placebo. The findings are discussed in context with other trials investigating neurohormonal blockade for the prevention of cancer therapy-related cardiac dysfunction.
摘要
本综述重点介绍了SARAH试验的结果，该试验评估了沙库巴曲缬沙坦在接受蒽环类化疗的患者中预防亚临床心脏功能障碍的疗效。与安慰剂相比，试验表明治疗组的左心室纵向应变（GLS）下降显著减少。本文结合其他研究神经激素阻断预防癌症治疗相关心脏功能障碍的试验对这些发现进行了讨论。
相似文献
1
The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.莎拉试验：关于神经激素阻滞剂在预防蒽环类药物所致心脏毒性中作用的更多证据。
Heart Fail Rev. 2025 May;30(3):627-631. doi: 10.1007/s10741-025-10495-1. Epub 2025 Feb 17.
2
Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial.沙库巴曲缬沙坦用于乳腺癌的心脏保护（MAINSTREAM）：随机试验的设计和原理。
ESC Heart Fail. 2023 Oct;10(5):3174-3183. doi: 10.1002/ehf2.14466. Epub 2023 Jul 14.
3
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.血管紧张素受体拮抗剂与中性内肽酶抑制剂联合使用
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
4
The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series.沙库巴曲缬沙坦在蒽环类药物所致心肌病中的应用：一个小型病例系列
J Oncol Pharm Pract. 2019 Jul;25(5):1231-1234. doi: 10.1177/1078155218783238. Epub 2018 Jun 27.
5
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.血管紧张素受体脑啡肽酶抑制剂可减轻实验性心力衰竭中的心肌重构并改善梗死区灌注。
Sci Rep. 2019 Apr 8;9(1):5791. doi: 10.1038/s41598-019-42113-0.
6
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.沙库巴曲缬沙坦双重抑制血管紧张素受体和中性肽链内切酶在慢性收缩性心力衰竭中的应用：解读新的PARADIGM研究
Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14.
7
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.沙库巴曲缬沙坦：心力衰竭治疗难题中的重要一环。
Rev Port Cardiol. 2017 Sep;36(9):655-668. doi: 10.1016/j.repc.2016.11.013. Epub 2017 Aug 23.
8
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.沙库巴曲缬沙坦：一种新型血管紧张素受体脑啡肽酶抑制剂。
Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S102-S110. doi: 10.1016/j.ihj.2018.01.002. Epub 2018 Jan 8.
9
Sacubitril/Valsartan: potential treatment for paediatric heart failure.沙库巴曲缬沙坦：小儿心力衰竭的潜在治疗方法。
Cardiol Young. 2018 Sep;28(9):1077-1081. doi: 10.1017/S1047951118001014. Epub 2018 Jul 6.
10
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.沙库巴曲缬沙坦抑制中性肽链内切酶治疗心力衰竭：性价比高的降低死亡率方法
J Clin Pharm Ther. 2016 Apr;41(2):119-27. doi: 10.1111/jcpt.12363. Epub 2016 Mar 18.
引用本文的文献
1
Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.心脏肿瘤学中不断发展的心脏保护策略：一篇叙述性综述
Curr Cardiol Rep. 2025 Sep 9;27(1):131. doi: 10.1007/s11886-025-02283-y.
2
Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.癌症治疗相关的心脏功能障碍：预防和治疗的最新进展
Life (Basel). 2025 Mar 15;15(3):471. doi: 10.3390/life15030471.
本文引用的文献
1
Anthracycline Cardiotoxicity in Adult Cancer Patients: State-of-the-Art Review.成年癌症患者的蒽环类药物心脏毒性：最新综述
JACC CardioOncol. 2024 Sep 17;6(5):655-677. doi: 10.1016/j.jaccao.2024.07.016. eCollection 2024 Oct.
2
Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial.化疗期间的压力监测以改善心血管结局：SUCCOUR-MRI 试验。
Eur Heart J. 2024 Nov 7;45(41):4414-4424. doi: 10.1093/eurheartj/ehae574.
3
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction.欧洲心脏病学会心脏肿瘤学指南生物标志物标准对癌症治疗相关心脏功能障碍发生率的影响
JACC CardioOncol. 2024 Jan 16;6(1):83-95. doi: 10.1016/j.jaccao.2023.10.008. eCollection 2024 Feb.
4
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.多中心、前瞻性、随机对照试验：高敏心肌肌钙蛋白 I 指导下的血管紧张素受体阻滞剂联合β受体阻滞剂治疗预防蒽环类药物心脏毒性：心脏 CARE 试验。
Circulation. 2023 Nov 21;148(21):1680-1690. doi: 10.1161/CIRCULATIONAHA.123.064274. Epub 2023 Sep 25.
5
Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.采用应变引导策略管理潜在心脏毒性的癌症治疗以实现心脏保护：SUCCOUR 试验 3 年结果。
JACC Cardiovasc Imaging. 2023 Mar;16(3):269-278. doi: 10.1016/j.jcmg.2022.10.010. Epub 2022 Nov 16.
6
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: State-of-the-Art Review.心脏保护在癌症治疗中的作用：心脏毒性——最新综述
JACC CardioOncol. 2022 Mar 15;4(1):19-37. doi: 10.1016/j.jaccao.2022.01.101. eCollection 2022 Mar.
7
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.辅助性乳腺癌治疗期间预防心脏功能障碍（PRADA II）试验的原理与设计：一项随机、安慰剂对照、多中心试验
Cardiooncology. 2021 Sep 27;7(1):33. doi: 10.1186/s40959-021-00115-w.
8
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.辅助乳腺癌治疗中心肌功能障碍的预防（PRADA）：坎地沙坦和倍他洛尔 2×2 析因、随机、安慰剂对照、双盲临床试验的延长随访。
Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16.
9
Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.左心室整体纵向应变评估对化疗诱导性心脏毒性早期预测的预后价值：系统评价和荟萃分析。
JAMA Cardiol. 2019 Oct 1;4(10):1007-1018. doi: 10.1001/jamacardio.2019.2952.
10
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.蒽环类药物诱导的心脏毒性：一项比较依那普利两种预防策略的多中心随机试验：国际心脏肿瘤学会一项试验。
Eur J Cancer. 2018 May;94:126-137. doi: 10.1016/j.ejca.2018.02.005. Epub 2018 Mar 20.
Zotero 插件